Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$0.93 USD
-0.03 (-2.92%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $0.95 +0.02 (2.15%) 7:28 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Oncolytics Biotech Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 26 | 25 | 33 | 23 | 11 |
Receivables | 0 | 0 | 1 | 0 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 2 |
Total Current Assets | 28 | 27 | 36 | 25 | 14 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 0 | 0 | 0 |
Total Assets | 29 | 29 | 37 | 26 | 15 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 7 |
Total Current Liabilities | 3 | 3 | 2 | 2 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 5 | 5 | 5 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 8 | 8 | 8 | 7 | 15 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 319 | 311 | 312 | 266 | 234 |
Capital Surplus | 31 | 31 | 27 | 23 | 22 |
Retained Earnings | -330 | -322 | -314 | -274 | -260 |
Other Equity | 0 | 1 | 3 | 3 | 3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | 20 | 29 | 18 | 0 |
Total Liabilities & Shareholder's Equity | 29 | 29 | 37 | 26 | 15 |
Total Common Equity | 20 | 20 | 29 | 18 | 0 |
Shares Outstanding | 74.40 | 61.30 | 55.00 | 41.60 | 32.20 |
Book Value Per Share | 0.27 | 0.33 | 0.52 | 0.44 | 0.00 |
Fiscal Year End for Oncolytics Biotech Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 18 | 22 | 26 | 30 | 18 |
Receivables | 1 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 2 | 4 | 5 |
Total Current Assets | 22 | 25 | 28 | 34 | 23 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 23 | 26 | 29 | 34 | 24 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 3 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 4 | 0 |
Total Current Liabilities | 4 | 3 | 3 | 7 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 5 | 5 | 5 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 9 | 8 | 13 | 7 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 318 | 321 | 319 | 320 | 308 |
Capital Surplus | 32 | 32 | 31 | 31 | 30 |
Retained Earnings | -336 | -336 | -330 | -329 | -321 |
Other Equity | 1 | 1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 13 | 17 | 20 | 22 | 17 |
Total Liabilities & Shareholder's Equity | 23 | 26 | 29 | 34 | 24 |
Total Common Equity | 13 | 17 | 20 | 22 | 17 |
Shares Outstanding | 76.80 | 75.40 | 74.40 | 73.40 | 65.70 |
Book Value Per Share | 0.17 | 0.23 | 0.27 | 0.29 | 0.25 |